期刊文献+

LC-MS/MS法测定人血浆中吡非尼酮及其代谢产物的浓度 被引量:2

Determination of pirfenidone and its major metabolite in human plasma by LC-MS/MS analysis
下载PDF
导出
摘要 目的建立LC-MS/MS法测定人血浆中吡非尼酮(pirfenidone,BT)及其主要代谢产物5-羧基吡非尼酮(5-carboxypirfenidone,SBT)的含量。方法血浆样品加入氘代同位素内标吡非尼酮-d5(d BT)和5-羧基吡非尼酮-d5(d SBT),经甲醇沉淀蛋白后进样。液相分离采用Agilent ZORBAX SB C18(3.0 mm×100 mm,3.5μm)色谱柱,流动相为水(含0.5%甲酸)/乙腈(50/50)。质谱检测采用ESI离子源,正离子多反应检测模式检测。BT、SBT、d BT和d SBT的检测目标离子对分别为m/z 185.958/77.1、215.944/77.0、190.965/81.1和220.948/99.1。结果空白溶剂、空白血浆无干扰,分析物及内标间无相互干扰。血浆中BT和SBT分别在0.020 59~25.14 mg·L-1和0.016 73~20.42 mg·L-1范围内线性关系良好。批内、批间精密度和准确度均在可接受范围内。分析物及内标储备液于4℃冰箱中放置156 d,血浆样本于室温放置4 h、-70℃冰箱中保存并反复冻融3次、-70℃冰箱保存10、29、52 d及样品处理后自动进样器(8℃)中放置24 h的情况下均稳定。BT和SBT的平均提取回收率和归一化基质因子均在可接受范围内。结论本研究所建立的测定BT和SBT血浆药物浓度的LC-MS/MS分析方法具有良好的特异性、准确度、精密度、灵敏度、稳定性和耐用性,适用于人血浆中吡非尼酮及其代谢物的浓度测定及其药动学研究。 Aim To establish a LC-MS/MS method for the determination of pirfenidone(BT)and its major metabolite 5-carboxy-pirfenidone(SBT)in human plasma.Methods Human plasma samples containing BT and SBT, as well as their corresponding deuterium-labeled internal standards pirfenidone-d5(dBT)and 5-carboxy-pirfenidone-d5(dSBT), were precipitated using methanol.Chromatographic separation was carried out on an Agilent ZORBAX SB C18(3.0 mm×100 mm, 3.5 μm)column with the mobile phase of water(0.5% formic acid)and acetonitrile(50/50).The detection of analytes was performed on a tandem mass system equipped with an electrospray ionization source in positive ion mode using multiple-reaction monitoring.The MS/MS ion transitions monitored were m/z 185.958→77.1 for BT, m/z 215.944→77.0 for SBT, m/z 190.965→81.1 for dBT and m/z 220.948→99.1 for dSBT.Results There was no remarkable interference in blank solvent, plasma, and there was no mutual interference between analytes or internal standards.The proposed method showed good linearity over the concentration range of 0.020 59-25.14 mg·L^-1 for BT and 0.016 73-20.42 mg·L^-1 for SBT.The intra-batch and inter-batch precision and accuracy were proved to be acceptable.Human samples kept stable after 4 h at room temperature, the three freeze-thaw cycles and 10, 29 and 52 days at -70 ℃, and the processed samples remained stable after 24 h in the autosampler.The average extraction recovery and matrix effect were precise, reproducible and acceptable.Conclusion Our current LC-MS/MS method is proved to be sensitive, accurate and convenient, and could be suitable for the clinical pharmacokinetic studies of BT-related preparations.
作者 李长印 宋慧婷 宗阳 张军 居文政 LI Chang-yin SONG Hui-ting ZONG Yang ZHANG Jun JU Wen-zheng(Dept of Clinical Pharmacology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029,China)
出处 《中国药理学通报》 CAS CSCD 北大核心 2017年第5期696-703,共8页 Chinese Pharmacological Bulletin
基金 国家自然科学基金青年项目(No 81503300) 江苏省中医院高峰人才项目(No y2014rc17) 江苏高校优势学科建设工程资助项目(2014)
关键词 吡非尼酮 5-羧基吡非尼酮 LC-MS/MS 人血浆药物浓度 药代动力学 多反应检测模式 pirfenidone 5-carboxy-pirfenidone LC-MS/MS human plasma concentration pharmacokinetics multi-reaction monitoring mode
  • 相关文献

参考文献7

二级参考文献46

  • 1夏玉叶,闵旸,盛雨辰.羟基红花黄色素A对大鼠血栓形成和血小板聚集功能的影响[J].中国药理学通报,2005,21(11):1400-1401. 被引量:34
  • 2王永升,赵小平,钟皎,陈燕,柳晓泉,王广基.HPLC-UV法测定比格犬血浆中吡非尼酮浓度及其药代动力学[J].中国药科大学学报,2006,37(2):146-149. 被引量:8
  • 3李欣志,刘建勋,尚晓泓,傅建华.羟基红花黄色素A对犬急性心肌缺血的保护作用[J].中国药理学通报,2006,22(5):533-537. 被引量:34
  • 4NICOD L P. Pirfenidone in idiopathic pulmonary fibrosis [ J]. Lancet, 1999,354(9175) :268-269.
  • 5GARC A L, HERN NDEZ I, SANDOVAL A, et al. Pirfenidone effectively reverses experimental liver fibrosis [ J ] . J Hepatol, 2002,37 ( 6 ) : 797-805.
  • 6MIRIC G, DALLEMAGNE C, ENDRE Z, et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats[ J]. Br J Pharmacol, 2001 , 133 (5) :687- 694.
  • 7AL-BAYATI M A, XIE Y, MOHR F C, et al. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats [J].Biochem Pharmacol, 2002,64 ( 3 ) :517-525.
  • 8TANIYAMA M, OHBAYASHI S, NARITA M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients[J]. Eur J Clin Pharmacol, 1997,52( 1 ) :77-78.
  • 9GIRI S N, WANG Q, XIE Y, et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration [ J ]. Biopharm Drug Dispos, 2002,23 (5) :203-211.
  • 10TANIYAMA M, OHBAYASHI S, NARITA M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients [ J]. Eur J Clin Pharmacol, 1997,52 ( 1 ) :77-78.

共引文献60

同被引文献6

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部